Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Items 301–400 of 476
Current status of prevention strategies adapted for Alzheimer's disease
Singh, A., Sethi, P., Ghosh, S., Singh, K. K., Rohatgi, S., Singh, P. K., & Sinha, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00004-5 · Cited by 6
Wang, Y., Guo, B., Zhao, K., Yang, L., & Chen, T. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1148518 · Cited by 6
“We reviewed the literature and found that serum P-tau181 and T-tau protein concentrations both had good correlations with their cerebrospinal fluid protein concentrations (Barthélemy et al., 2020; Janelidze et al., 2020) and can be used as serum biomarkers of cognitive impairment in PE patients.”
BackgroundFu, S.-Y., Zheng, Q., Xu, B., & Chen, F. (2025) · View · doi:10.1002/viw.20240119 · Cited by 5
Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
Marotta, C., González‐Ortiz, F., Turton, M., Zetterberg, H., Harrison, P., Hovens, C. M., Sinclair, B., O'Brien, T. J., Blennow, K., & Vivash, L. E. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70123 · Cited by 6
Biomarkers in CNS Drug Discovery, Drug Development, and Clinical Implementation
Caro, V. D., Williams, C., North, H. A., & Hamby, M. E. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch7 · Cited by 5
Predictive Value of Plasma Biomarkers in Tau‐ PET Transitions
Graff‐Radford, J., Syrjanen, J. A., Vemuri, P., Lowe, V. J., Schwarz, C. G., Wiste, H. J., Kremers, W. K., Algeciras‐Schimnich, A., Binette, A. P., Smith, R. A., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78003 · Cited by 5
Kjærgaard, D., Simonsen, A. H., Stomrud, E., Bali, D., Janelidze, S., Hansson, O., Waldemar, G., & Nielsen, T. R. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123739 · Cited by 5
Tsurumi, A., Cahill, C. M., Liu, A., Chatterjee, P., Das, S., & Kobayashi, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311673 · Cited by 5
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 5
Yuan, S., Essepian, N., Roberts, R., Sherman, E., Gniadzik, W. M., Wang, Q., Erisir, A., & Jiang, L. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03018-1 · Cited by 5
“The live-cell time-lapse imaging showed that tau oligomerization, an early process in tauopathies [5, 22, 32, 46], initiated rapid and significant nuclear membrane deformation.”
Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer’s Disease
Tu, L. M. T. P. P. L. M., Hoang, T. X., Thu, V. T. A., Kim, J. Y., Lee, S.-M., Cho, W. W., Kim, Y. H., Choi, S. H., & Cho, S. (2020) · Diagnostics · doi:10.3390/diagnostics10110913 · Cited by 5
“In parallel with amyloidosis, Tau, a microtubule-binding protein phosphorylated and accumulated into neurofibrillary tangles (NFT), is reflected as a second biomarker for AD [17].”
BackgroundLeón‐Espinosa, G., Murillo, A. M., Turégano-López, M., DeFelipe, J., & Holgado, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-71481-5 · Cited by 5
“Concerning the third point, Barthélemy et al. indicated that peripheral contribution has a different phosphorylation pattern compared to CSF and this may affect the search for pTau biomarkers 10 .”
BackgroundBlood-Based Protein Biomarkers in the Chronic Phase of Traumatic Brain Injury: A Systematic Review
Hicks, A. J., Carrington, H., Bura, L., Yang, A., Pesce, R., Yew, B., & Dams-O’Connor, K. (2025) · Journal of Neurotrauma · doi:10.1089/neu.2024.0294 · Cited by 6
“95 One study in our review did include both total tau and bd-tau, and although no statistical comparisons were made, the authors reported that bd-tau was a more sensitive marker and CNS-tau signal could be masked when total tau was used.”
Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 5
Thanapornsangsuth, P., Ongphichetmetha, T., Luechaipanit, W., Hemachudha, P., & Hemachudha, T. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12358 · Cited by 5
Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
Hsiao, W. W., Angela, S., Le, T., Ku, C., Hu, P., & Chiang, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221202 · Cited by 5
Таскина, Е. С., Владимировна, К. И., Мудров, В. А., & Давыдов, С. О. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-cmo-3169 · Cited by 4
Plasma biomarkers in neuropsychiatric syndromes: A narrative review
Ismail, Z., Guan, D. X., Babulal, G. M., Bateman, J. R., Cantillon, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ghahremani, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392185 · Cited by 4
“For example, concentrations of plasma A β 4237 and tau 38 are approximately 30 and 2 – 5 times lower, respectively, than in CSF.”
Wang, J., Yao, K.-Y., Li, J., Wong, D. W., & Cheung, J. C. (2025) · Biosensors · doi:10.3390/bios15120784 · Cited by 4
“Among these markers, phosphorylated tau proteins (p-tau) are the most promising blood biomarkers for AD research [17].”
Mattsson, N., Karlsson, L., Tang, W., Blennow, K., Zetterberg, H., Bateman, R. J., Schindler, S. E., Barthélemy, N. R., Palmqvist, S., Stomrud, E., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00348-7 · Cited by 4
“Plasma and CSF levels of P-tau181, and P-tau217, together with plasma levels of P-tau205 were measured in BioFINDER-2 using liquid chromatography-tandem mass spectrometry (LC-MS/MS) at the Department of Neurology, Washington University School of Medicine (Barthélemy et al, 2020).”
Self-citationBlood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries
Halbgebauer, R., González‐Ortiz, F., Mayer, B., Berger, C., Bergmann, C. B., Rinderknecht, H., Barth, E., Wohlgemuth, L., Mannes, M., Otto, M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.58573 · Cited by 4
Shoff, T. A., Derbez-Morin, M., Cai, P., & Julian, R. R. (2026) · PNAS Nexus · doi:10.1093/pnasnexus/pgag034 · Cited by 5
Hoshi, K., Kanno, M., Abe, M., Murakami, T., Ugawa, Y., Goto, A., Honda, T., Saito, T., Saido, T. C., Yamaguchi, Y., et al. (2022) · Metabolites · doi:10.3390/metabo12040355 · Cited by 4
Wan, Z., & Ma, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0303486 · Cited by 4
“In addition, plasma and cerebrospinal fluid (CSF) phosphorylated tau (p-tau), particularly its isoform p-tau181 and p-tau217, are recognized as potential biomarker for early onset AD in preclinical settings and the level of p-tau has been associated with the intensity of tauopathy [24–29].”
The present and future of minimally invasive methods for Alzheimer's disease diagnosis
Oh, I.-H., Shin, W., Ahn, J., Lee, J.-P., Min, J., Ahn, J., & Kim, Y. (2022) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-022-00144-7 · Cited by 4
“Therefore, in a recently presented paper, plasma tau was concentrated and analyzed through nano-flow capillary liquid chromatography with nano-electrospray MS/MS [46].”
MethodThe Alzheimer disease continuum : findings from monogenic Alzheimer disease
Johansson, C. (2025) · doi:10.69622/28639856 · Cited by 4
Gothwal, A., Muolokwu, C. E., Chaulagain, B., Mahanta, A. K., & Singh, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143542 · Cited by 3
Shahim, P., Alqahtani, A. A., Kokkinis, A. D., Kazmi, N., Ezuma-Ngwu, M., Misra, J., Harmison, G. G., Benoit, N. E., Jones, M., Howe, E., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf275 · Cited by 3
Kara, F., Joers, J. M., Przybelski, S. A., Algeciras‐Schimnich, A., Gunter, J. L., Jack, C. R., Petersen, R. C., Öz, G., & Kantarci, K. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.11.003 · Cited by 3
Vigneswaran, S., Verberk, I. M. W., Rousset, R. Z., Gouda, M., Trieu, C., Claessen, T., van de Giessen, E., Lemstra, A. W., Wilson, D. J., Pijnenburg, Y. A. L., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01979-9 · Cited by 3
Zhang, Y., An, Y., Yang, M., Huang, Y., Yu, S., Xu, X., & Yang, C. J. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.139727 · Cited by 3
Lung endothelial cytopathic tau is sufficient to impair long-term potentiation during infection
Lin, M. T., ALEXEYEV, M. F., Körbelin, J., Zhou, C., Chaney, S. D., Choi, C., Shastri, C., Bernal, H. C., Chen, N., Stone, M., et al. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag040 · Cited by 3
“The prevailing dogma is that tau in the circulation mostly reflects neuronal activity (75, 76).”
Advances and emerging challenges in detecting Tau proteoforms for Alzheimer's disease diagnosis
Cai, Q., Miao, M., & Li, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118897 · Cited by 3
Xu, J., & Costen, F. (2026) · Diagnostics · doi:10.3390/diagnostics16121755 · Cited by 3
Lee, J., Olafson, E., Toth, B., Casavant, E., Schauer, S. P., Bittner, T., Meyer, M. R., Verghese, P. B., Venkatesh, V., West, T., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71604 · Cited by 3
Sharma, A., Feng, L., Muresanu, D. F., Tian, Z. R., Lafuente, J. V., Buzoianu, A. D., Nozari, A., Bryukhovetskiy, I., Manzhulo, I., Wiklund, L., et al. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.05.009 · Cited by 3
Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ?
Delaby, C., & Lehmann, S. (2024) · médecine/sciences · doi:10.1051/medsci/2024037 · Cited by 4
Prospective use of miRNAs as biomarkers in the diagnosis of Alzheimer’s disease
Haśko, A., Potocka, N., Skrzypa, M., Bartosik-Psujek, H., & Zawlik, I. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/190273 · Cited by 3
New Research on Biomarkers in Alzheimer’s Continuum
Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615 · Cited by 3
Guo, Z., Zhang, C., Wang, X., Chen, W., & Guo, Z. (2025) · Brain and Behavior · doi:10.1002/brb3.70436 · Cited by 3
“…Alzheimer’s disease (AD) biomarkers such as β -amyloid 40 (A β 40), β -amyloid 42 (A β 42), phosphorylated tau (Ptau), and total tau (Ttau), is closely related to AD, POD, and other central nervous system diseases (Barthélemy et al. 2020; Reiss et al. 2018; Salvadores et al. 2020; Yan et al. 2020).”
Sood, A., Pavlik, V., Darby, E. J., Chan, W., & Doody, R. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201124 · Cited by 3
Xia, C., & Ma, Q. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/7135399 · Cited by 3
RetractedAvances y desafíos en la investigación de la enfermedad de Alzheimer
Llibre-Rodriguez, J. D. J., & Herrera, R. F. G. (2024) · Anales de la Academia de Ciencias de Cuba · Cited by 3
Tau species has potential for Alzheimer disease blood test
Fyfe, I. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0401-z · Cited by 3
Balcı, E. B., Yildiz, E. N., Oksuz, S. S., Ahmadli, N., Kargidan, M., Ayyildiz, N., Alemdar, E., Uludag, I., & Hasirci, U. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.10.602686 · Cited by 3
“It is also found that p-tau181 and p-tau217 have the highest selectivity for diagnosis of the disease as blood biomarkers [9].”
BackgroundBaron, S. K. V. (2024) · theses.fr (ABES) · doi:10.70675/652f012dz5154z4a59z9326zdc0fca7e4638 · Cited by 3
A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
Paterno, G., Bell, B. M., Gorion, K.-M. M., Quintin, S. S., Prokop, S., & Giasson, B. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-04291-y · Cited by 2
Hellquist, E., Janelidze, S., Weidung, B., Franzon, K., Giedraitis, V., Ingelsson, M., Bali, D., Veličkaitė, V., Zetterberg, H., Hansson, O., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251390387 · Cited by 2
“12,18 In brief, plasma p-tau 217 increases from the stage of PET amyloid-positivity and tau-negativity before cognitive impairment, 19 and further on to AD MCI and mild AD dementia.”
InfluentialGoonetilleke, U. K. D. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-0523-1_35 · Cited by 2
Proteome-Based Biomarkers for Alzheimer’s Disease: Old Acquisitions and Innovative Proposals
Magnelli, V., Pagano, C. A., & Sabbatini, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311654 · Cited by 2
Shrestha, S., Zhu, X., Windham, B. G., Sullivan, K. J., Palta, P., Gottesman, R. F., Tracy, R. P., Jack, C. R., Cogswell, P. M., Vemuri, P., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71422 · Cited by 2
Molecular and statistical weaknesses of the p-tau217/Aβ1−42 plasma ratio for alzheimer’s diagnosis
Griñán‐Ferré, C., Pallàs, M., & Franco, R. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02676-8 · Cited by 2
“Phosphorylation at threonine 217 (T217), located within the proline-rich P1 domain of tau [13–15], has emerged as a candidate biomarker for AD.”
Chen, X., Huang, T., Shi, C., Xu, S., & Fan, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1834591 · Cited by 2
Chai, L., Zhan, Y., Huang, Y., Tian, M., Zhao, G., Ni, J., Xiong, X., Huang, J., & Lin, B. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02104-6 · Cited by 2
Fung, H. T., Burton, O., Bortnowschi, M., Matthews, P. M., Parkes, L. M., Zetterberg, H., Hainsworth, A. H., & Geranmayeh, F. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71653 · Cited by 2
Balogun, W. G., Zeng, X., Nafash, M. N., Sehrawat, A., Shi, R., Svirsky, S. E., Okonkwo, D. O., Puccio, A. M., & Karikari, T. K. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70518 · Cited by 2
“However, their presence in peripheral tissue introduces variability, as cerebrospinal fluid (CSF) measurements may differ from blood measurements due to peripheral contributions, particularly in the case of tau (Barthélemy et al. 2020; Fischer and Baas 2020; Müller et al. 2017).”
Dey, K. K., Yarbro, J. M., Liu, D., Han, X., Wang, Z., Jiao, Y., Wu, Z., Yang, S., Lee, D. G., Dasgupta, A., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00496 · Cited by 2
Walia, A., Shew, M. A., Durakovic, N., Herzog, J. A., Cirrito, J. R., Yuede, C. M., Wick, C. C., Manis, M., Holtzman, D. M., Buchman, C. A., et al. (2024) · Otolaryngology · doi:10.1002/ohn.942 · Cited by 2
“…A β 42 levels by 5 to 6×, similar to the ∼ 10× difference reported in CSF. 54 tTau levels in perilymph were ∼ 15 to 30× lower than those in CSF. 23 While the extent of communication between CSF and perilymph in human is not clear, these differences in detected levels suggest the cochlear fl uid…”
InfluentialHassouneh, A., Danna‐dos‐Santos, A., Bazuin, B. J., Shebrain, S., Abdel-Qader, I. M., & Initiative, O. B. O. T. A. D. N. (2024) · Digital Biomarkers · doi:10.1159/000543165 · Cited by 2
Liu, Y., Liu, X., Che, P., Wang, Y., Piao, Z., Wang, Y., Cai, L., Xing, M., Xu, Y., Sun, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83919-x · Cited by 2
“spectrometry (IP-MS) 14–16 .”
Historical efforts to develop 99mTc-based amyloid plaque targeting radiotracers
Takalloobanafshi, G., Kukreja, A., & Hicks, J. W. (2022) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2022.963698 · Cited by 2
Identification de biomarqueurs sanguins chez des sujets à risque pour la maladie d’Alzheimer
Potier, M. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.02.003 · Cited by 2
Yue, K., Webster, J. M., Grabowski, T. J., Jahanian, H., & Shojaie, A. (2025) · Aperture Neuro · doi:10.52294/001c.141445 · Cited by 2
Lussier, F. Z., Benedet, A. L., Therriault, J., Pascoal, T. A., Tissot, C., Chamoun, M., Mathotaarachchi, S. S., Savard, M., Ashton, N. J., Karikari, T. K., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-69968/v1 · Cited by 2
“plasma and serum) using ultrasensitive immunoassays[9–13] and mass spectrometry methods[14].”
MethodAgostini, M., Traldi, P., & Hamdan, M. H. (2025) · NeuroSci · doi:10.3390/neurosci6020050 · Cited by 1
“…isoforms of p-tau, such as p-tau181, p-tau217, and p-tau231, can be detected in plasma with high accuracy; these entities have been the subject of various investigations and some clinical trials to explore their potential as blood-based markers for an early and accurate diagnosis of AD [76–78].”
Tau proteoforms as plasma biomarkers in Alzheimer’s disease: mechanisms, measurement, and medicine
Kim, E., Lee, J. H., & Han, D. (2026) · Expert Review of Proteomics · doi:10.1080/14789450.2025.2611853 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
Fernandes, M. G. F., Pinard, M., Sokullu, E., Tremblay, C., Gagnon, J., Calon, F., Coulombe, B., & Brouillette, J. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag009 · Cited by 1
The fluid biomarkers of Alzheimer’s disease
Peng, Q., & Zhang, Z. (2021) · Brain Science Advances · doi:10.26599/bsa.2021.9050001 · Cited by 1
Development of Fluid Biomarkers for Alzheimer’s Disease
Blennow, K. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.033 · Cited by 1
Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease
Jethwa, A., & Stöckl, L. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3774-6_5 · Cited by 1
Major or Mild Vascular Neurocognitive Disorder
Espiritu, A. I., Balakrishnar, K., Moradizadeh, M., Marlatt, N. E., & Burhan, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-47802-4_21 · Cited by 1
Linking evidence for targeted blood biomarkers in post-stroke cognitive impairment and dementia
Hong, J., Mun, K. T., Kern, K. C., Thirion, M. L., & Hinman, J. D. (2025) · Frontiers in Stroke · doi:10.3389/fstro.2024.1491542 · Cited by 1
Research Progress on Alzheimer's Disease Biomarkers Based on the ATX(N) Framework
Cao, H., Zhang, W., Lin, J., & Yu, E. (2025) · Discovery Medicine · doi:10.24976/discov.med.202537193.21 · Cited by 1
Rich, A., Oh, H., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361354 · Cited by 1
Chen, T., Wang, Y., Wang, K., Zhu, P., Guo, Y., Yang, L., & Nie, W. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-08553-5 · Cited by 1
“We reviewed the literature and found that the concentrations of serum Aβ1-42, T-tau, and P-tau181 proteins were all strongly correlated with the concentrations in cerebrospinal fluid [31, 32].”
Sari, C. P., Situmeang, R. F. V., & Meriyanti, T. (2026) · Lumina Indonesian Journal of Neurology · doi:10.19166/lijn.v2i1.11078 · Cited by 1
Zapater‐Fajarí, M., Bucci, M., Chiotis, K., Almkvist, O., Wall, A. E., Eriksson, J., Antoni, G., Pola, I., Tan, K., Traichel, W., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08015-w · Cited by 1
“Because CSF p-tau217 better detects amyloid pathology and aligns more closely with plasma p-tau217 [57], the lack of correlation between plasma p-tau217 and CSF p-tau181 in our cohort likely indicate that these markers capture related but biologically distinct aspects of AD pathophysiology.”
Delaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
Immunomagnetic reduction detects amyloid β 1–42, but neither x –42 nor 1– y
Liu, H.-C., Lin, C.-Y., Ho, C.-S., Chang, J.-F., Lee, K.-H., & Yang, S. (2026) · RSC Advances · doi:10.1039/d6ra01450j · Cited by 1
Ultrasensitive Assay Technologies
Yang, C. S.-Y., & Sabbagh, M. N. (2026) · Springer eBooks · doi:10.1007/978-3-032-23863-4_1 · Cited by 1
The future of dementia prevention and treatment strategies
直行, 里. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.374 · Cited by 1
AAIC 2020: Unprecedented success in an unprecedented time
(2020) · Alzheimer s & Dementia · doi:10.1002/alz.12200 · Cited by 1
“The study found that the blood test (1) couldmore accurately distinguishAD fromother forms of dementia than other blood tests; (2) was as accurate as other moreexpensive and invasivediagnostic tools; and (3) coulddetect brain changes almost 20 years before the expected onset of symptoms of cognitive decline.”
ResultEmerging blood-based biomarkers for Alzheimer disease
Bekris, L. M., & Leverenz, J. B. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20133 · Cited by 1
Blood biomarkers in MCI conversion to Alzheimer’s disease: a systematic review and meta-analysis
Li, H., Wang, J., Dong, Y., Li, J., Xiao, J.-W., Ren, R., Li, C., & Wang, G. (2023) · Human Brain · doi:10.37819/hb.2.1758 · Cited by 1
Piccirella, S., Cristoni, S., Fowler, C. J., Doecke, J. D., Abate, G., & Uberti, D. L. (2021) · Preprints.org · doi:10.20944/preprints202101.0530.v1 · Cited by 1
“Recent studies attempted to identify blood-derived biomarkers for less invasive tests (Aβ1-40/42, tau total and p-tau181 or p-tau217, microRNAs or neurofilament NfL), but the diagnosis is often in the shorter range of MCI, too late for a precocious intervention (6-10).”
BackgroundAlzheimer’s disease in primary care: new tools for improved and simplified diagnostics
Zetterberg, H., & Stomrud, E. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13249 · Cited by 1
“The CSF tests have recently been developed into blood-based tests with surprisingly good diagnostic accuracy [5]; some studies even suggest that they can replace the imaging and CSF biomarkers altogether [6, 7].”
BackgroundBazan, N. G., Bhattacharjee, S., Kala-Bhattacharjee, S., Ledet, A. J., & Mukherjee, P. K. (2023) · Research Square · doi:10.21203/rs.3.rs-3185942/v1 · Cited by 1
Vrillon, A. (2022) · theses.fr (ABES) · doi:10.70675/58f64870z23eaz429bz9f78z6d92e769384b · Cited by 1
Emerging Biomarkers for Early Detection of Alzheimer’s Disease: A Systematic ReviewPreprint
Desai, C., Rathod, S., Daulti, T., Prajapati, M., Malkan, S., & Bhamwani, M. (2024) · medRxiv · doi:10.1101/2024.10.16.24315604 · Cited by 1
“Additionally, it is discovered that as blood biomarkers, p-tau181 and p-tau217 offer the highest selectivity for illness diagnosis [15].”
BackgroundMorgado, B. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11551 · Cited by 1
Mikrovesikel im Blut von Alzheimerpatienten
Fuchs, C. (2023) · Cited by 1
Park, J. Y., Guen, Y. L., Peña‐Tauber, A., & Greicius, M. D. (2026) · medRxiv · doi:10.64898/2026.07.01.26356385 · Cited by 1
Park, K. H., Jang, J., Suh, J., Yi, S., Bae, J., Lim, J., Lee, H., Chin, J., Park, Y. H., Hong, Y. J., et al. (2022) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2022.21.2.45
Biomarkers in cerebrospinal fluid and blood aid diagnosis of dementia
Rosenberg, G. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823455-6.00001-8
Schröder, H., de Vos, R. A. I., Huggenberger, S., Müller-Thomsen, L., Rozemüller, A. J. M., Hedayat, F., & Moser, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-89980-6_13
Application of Proteomics in Alzheimer’s Disease: A Mini Review
Sukumaran, P., Bahardin, A. A., Razak, L. H. A., & Senik, M. H. (2023) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.19.5.38
Xu, L., Ren, C., Jing, C., Wang, G., Wei, H., Kong, M., Ba, M., & Initiative, A. D. N. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16376
“It can also identify A β -PET ( + ) individuals (including those with clinical diagnosis of CN, MCI, or dementia) because of its high specificity for A β plaque pathology (Barthélemy et al., 2020; Ni et al., 2023).”
BackgroundClinical Assessment of a Plasma AT(N) Panel for Alzheimer’s DiseasePreprint
Collier, B. B., Chappell, M. R., Brandon, W. C., Le, T. V., Harris, A. B., Volpe, J. M., Martone, R. L., Winslow, J. W., Boles, D., Valcour, A., et al. (2024) · medRxiv · doi:10.1101/2024.08.06.24310938
Role of tanycytes in Tau clearance and their relevance in Alzheimer's disease
Sauvé, F. (2022) · theses.fr (ABES) · doi:10.70675/25300be3z6219z4081z98a4z9dbe9641b2d2
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.